Jörg Trojan
YOU?
Author Swipe
View article: Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis
Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis Open
Background The incidence of severe immune-related hepatitis (irHepatitis) Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4 under combination therapy with ipilimumab and nivolumab ranges from 15% to 20%. Current clinical …
View article: German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus—version 4.0
German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus—version 4.0 Open
This guideline for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus was developed and managed by the German Guideline Program in Oncology (GGPO) of the Association of the Scientific Medical Societi…
View article: New perspectives in biliary tract cancers
New perspectives in biliary tract cancers Open
Biliary tract cancer (BTC) is a rare but highly lethal malignancy. Despite recent advances in diagnosis and treatment, the overall prognosis remains dismal, with a median survival of <1 year in most cases. This highlights an urgent medical…
View article: Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial
Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial Open
Introduction: The tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib represent the first-line systemic therapy of choice for patients with hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). Under sorafenib …
View article: Retrospective Long-Term Evaluation of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma over 20 Years
Retrospective Long-Term Evaluation of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma over 20 Years Open
The aim of this study was to retrospectively evaluate the effects of conventional transarterial chemoembolization (cTACE) for the treatment of hepatocellular carcinoma over 20 years regarding overall survival (OS) and prognostic factors fo…
View article: Heterogeneity of small duct‐ and large duct‐type intrahepatic cholangiocarcinoma
Heterogeneity of small duct‐ and large duct‐type intrahepatic cholangiocarcinoma Open
Aims The histological subtype of intrahepatic cholangiocarcinoma (iCCA) is associated with different mutational characteristics that impact clinical management. So far, data are lacking on the presence of small duct iCCA (SD‐iCCA) and larg…
View article: Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?
Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions? Open
Liver cancer was the fourth leading cause of cancer death in 2015 with increasing incidence between 1990 and 2015. Orthotopic liver transplantation, surgical resection and ablation comprise the only curative therapy options. However, due t…
View article: Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114)
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114) Open
Introduction: S-1 has been shown to be an effective adjuvant treatment option for East Asian patients who underwent gastrectomy for stage II/III gastric cancer. We conducted a phase I/II study to evaluate the feasibility, tolerability, and…
View article: Supplementary Figure S6 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Figure S6 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 193 KB, MutL� structure and the effects of substitutions on stability. Cartoon representation of the N- (top) and C-terminal (bottom) domains of MutL�; for better visibility, both domains are rotated against each other. MLH1 is …
View article: Supplementary Figure S1 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Figure S1 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 41 KB, Calibration data of the hMLH1 qPCR. Serial dilutions of a plasmid vector containing the MLH1 cDNA were produced, and aliquots of these dilutions were subject to quantitative PCR for MLH1 as detailed above. Cq values were …
View article: Supplementary Tabe S1 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Tabe S1 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 167 KB, This table contains the source information underlying Table 1 and Figure 2 of the main manuscript.
View article: Supplementary Figure S4 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Figure S4 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 56 KB, Microsatellite stability in cultured HEK293 cells. HEK293 and HEK293T cells, each derived from a previously singularized clone, were singularized in 96-well plates. DNA was extracted from colonies after 14 days by resuspe…
View article: Supplementary Figure S3 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Figure S3 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 75 KB, Proteolytic and thermal stability of MLH1 variants. A. Pulse-chase kinetics of MLH1 variants. MLH1 was co-expressed with PMS2 in vitro using pcDNA3-MLH1 and pSG5-PMS2 vectors in the presence of 35S-methionine (EasyTag Met…
View article: Supplementary Figure S2 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Figure S2 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 67 KB, MLH1 mRNA and protein levels after transfection (assay validation). A. HEK293T cells were transiently co-transfected with increasing amount of MLH1-PMS2 expression vectors (1-10 �g). Cells were harvested after 48 h and to…
View article: Supplementary Figure S7 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Figure S7 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 153 KB, MutL� structure and the effects of substitutions on repair. The MutL� structural model is shown as described in Supplementary Figure S6. The location of all residues whose substitutions have been investigated in this stu…
View article: Supplementary Table S3 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Table S3 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 100 KB, Statistical analysis of expression
View article: Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers Open
Background and Aims: Biliary tract cancers are rare, heterogeneous cancers with poor prognoses. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β “trap”) fused to a huma…
View article: Data from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Data from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
Purpose: Lynch syndrome is caused by a germline mutation in a mismatch repair gene, most commonly the MLH1 gene. However, one third of the identified alterations are missense variants with unclear clinical significance. The functionality o…
View article: Supplementary Figure S5 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Figure S5 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 81 KB, MAPP-MMR evaluation of the investigated MLH1 variants. MAPP-MMR (Multivariate Analysis of Protein Polymorphism-Mismatch Repair) values were calculated for all variants investigated in this study. Their individual dots in …
View article: Supplementary Figure S5 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Figure S5 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 81 KB, MAPP-MMR evaluation of the investigated MLH1 variants. MAPP-MMR (Multivariate Analysis of Protein Polymorphism-Mismatch Repair) values were calculated for all variants investigated in this study. Their individual dots in …
View article: Data from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Data from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
Purpose: Lynch syndrome is caused by a germline mutation in a mismatch repair gene, most commonly the MLH1 gene. However, one third of the identified alterations are missense variants with unclear clinical significance. The functionality o…
View article: Supplementary Table S2 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Table S2 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 120 KB, Clinical evaluation of additional MLH1 variants indicated in gray in Figure 4
View article: Supplementary Figure S2 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Supplementary Figure S2 from Expression Defect Size among Unclassified <i>MLH1</i> Variants Determines Pathogenicity in Lynch Syndrome Diagnosis Open
PDF file - 67 KB, MLH1 mRNA and protein levels after transfection (assay validation). A. HEK293T cells were transiently co-transfected with increasing amount of MLH1-PMS2 expression vectors (1-10 �g). Cells were harvested after 48 h and to…